Drug Profile
Research programme: Alzheimer's disease therapeutics - Astellas Pharma/RIKEN
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Astellas Pharma; RIKEN
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Alzheimer's-disease in Japan
- 08 Nov 2011 Early research in Alzheimer's disease in Japan (unspecified route)